Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up

Aim. To study the clinical course specifics of coronavirus disease 2019 (COVID-19) and comorbid conditions in COVID-19 survivors 3, 6, 12 months after recovery in the Eurasian region according to the AKTIV register. Material and methods.The AKTIV register was created at the initiative of the Eurasian Association of Therapists. The AKTIV register is divided into 2 parts: AKTIV 1 and AKTIV 2. The AKTIV 1 register currently includes 6300 patients, while in AKTIV 2 — 2770. Patients diagnosed with COVID-19 receiving in- and outpatient treatment have been anonymously included on the registry. The following 7 countries participated in the register: Russian Federation, Republic of Armenia, Republic of Belarus, Republic of Kazakhstan, Kyrgyz Republic, Republic of Moldova, Republic of Uzbekistan. This closed multicenter register with two nonoverlapping branches (in- and outpatient branch) provides 6 visits: 3 in-person visits during the acute period and 3 telephone calls after 3, 6, 12 months. Subject recruitment lasted from June 29, 2020 to October 29, 2020. Register will end on October 29, 2022. A total of 9 fragmentary analyzes of the registry data are planned. This fragment of the study presents the results of the post-hospitalization period in COVID-19 survivors after 3 and 6 months. Results. According to the AKTIV register, patients after COVID-19 are characterized by long-term persistent symptoms and frequent seeking for unscheduled medical care, including rehospitalizations. The most common causes of unplanned medical care are uncontrolled hypertension (HTN) and chronic coronary artery disease (CAD) and/or decompensated type 2 diabetes (T2D). During 3- and 6-month follow-up after hospitalization, 5,6% and 6,4% of patients were diagnosed with other diseases, which were more often presented by HTN, T2D, and CAD. The mortality rate of patients in the post-hospitalization period was 1,9% in the first 3 months and 0,2% for 4-6 months. The highest mortality rate was observed in the first 3 months in the group of patients with class II-IV heart failure, as well as in patients with cardiovascular diseases and cancer. In the pattern of death causes in the post-hospitalization period, following cardiovascular causes prevailed (31,8%): acute coronary syndrome, stroke, acute heart failure. Conclusion. According to the AKTIV register, the health status of patients after COVID-19 in a serious challenge for healthcare system, which requires planning adequate health system capacity to provide care to patients with COVID-19 in both acute and post-hospitalization period

Implementing experiential learning activities in a large enrollment introductory food science and human nutrition course

Experiential learning activities are often viewed as impractical, and potentially unfeasible, instructional tools to employ in a large class. Research has shown, though, that the metacognitive skills that students utilize while participating in experiential learning activities enable students to assess their true level of understanding and mastery for the subject matter. The objective of this study was to evaluate whether students in a large (~660 person) Introduction to Food Science and Human Nutrition (FSHN 101) course improved their understanding of dietary intake and food safety after participating in two experiential learning activities developed for these course topics. The first activity, completed during class, asked students to select one day???s worth of food from a list of menu choices, calculate the nutritional value of their food choices, and then compare their daily nutritional intake to the dietary reference intakes for their gender, age category and health status. The second activity, completed via the course website, asked students to complete one food safety survey prior to the commencement of the course???s food microbiology section to assess the students' personal food safety behaviors and a second survey upon completion of the section to assess students' knowledge of recommended food safety practices. Students were asked to evaluate both the cognitive and affective aspects of the experiential learning activities by completing a reflective questionnaire after participating in each activity. Overall, students' responses revealed that the activities were effective learning tools and that the students liked engaging with the material on a personal application level. A Poster version of this article can be found in the IDEALS SoTL Presentations and Posters folder.published or submitted for publicationis peer reviewe

THE PROPANORM EFFICACY IN RAPID RELIEF OF SYMPTOMS OF PAROXYSMAL AURICULAR FIBRILLATION

In aim to study efficacy and safety of propafenone (Propanorm), open prospective поп randomized study in-patients with paroxysmal form of auricular fibrillation (AF) was carried out. 31 patients - 16 men (51,6 % ) and 15 women (48,4 % ) with mean age 58, 1± 8 years were included in the study. The paroxysmal form AF was observed in 29 patients (93,5 % ), persistent form - in 2 patients (6,5 % ). The reason of arrhythmia in 21 patients (67,7 % ) was ischemic heart disease, in 12 patients (38,7 % >) - arterial hypertension, in 2 patients (6,4 % ) - rheumatic heart diseases, in 1 patient (3,2 % ) - idiopathic AF. The medication for rapid relief of symptoms of paroxysmal auricular fibrillation was administered in single stress dose 600 mg per os. Propanorm restored the rhythm in 74,2 % > patients. The disorder of intraventricular conduction on EKG became evi-dentin 7 patients (22,5 % ) in time from 2to 16. 5 hours (on average 5, 1 hour), atrioventricular heart block of I stage - in 2 patients (6,45 % ), aberrant ventricular complex - in 2 patients (6,45 % ), pacemaker migration and sinus bradycardia - in 1 patient (3,2 % ). This disorders eliminated independently without special intervention. Extracardiac side effects during single intake were not observed. Propafenone appeared to be high-performed antiarrhythmic medication in rapid relief of symptoms of paroxysmal auricular fibrillation. Its application is possible in the outpatient setting

EFFICACY AND SAFETY OF ALBAREL IN PATIENTS WITH MILD, MODERATE AND SEVERE HYPERTENSION

The aim of the study was to evaluate the efficacy and safety (influence on carbohydrate, lipid and mineral metabolism, as well as nitrogen-excreting function of kidneys) of monotherapy with rilmenidine in patients with mild to moderate AH, as well as treatment of patients with severe AH as multiple combined treatment. 43 patients with essential AH I-HI degree, aged 22 to 79, were enrolled in this open label study after signing an informed consent form. Enrolled patients were divided into 2 groups. Group 1 included 20 outpatients. They received monotherapy with rilmenidine 1 mg daily. Duration of treatment was 12 weeks. Group 2 was comprised of 23 subjects admitted to an in-patient clinic. Those subjects received Albarel 1 mg or 2 mg daily as a component of multiple antihypertensive therapy. Albarel was administered 7-10 days following the admission to clinic as a second to fifth hypotensive drug. Albarel's combinations with diuretics, ACE inhibitors, calcium antagonists, beta-blockers. The result is - monotherapy with Albarel 1-2 mg daily allows to achieve target BP in 77, 8 % patients with mild to moderate AH. With Albarel as a component of multiple therapy target BP is achieved in 65, 2 % patients with severe AH. Effectively decreasing BP Albarel does not change its daily profile. It has no influence on renal function, carbohydrate metabolism, and electrolyte content of blood. Albarel is well tolerated. Adverse effects included mouth dryness and drowsiness, was noted in 2, 33 % cases and did not require drug withdrawal